Jacobio Pharma announced it received IND approval of its self-developed drug JAB-30300 from the FDA of the U.S. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the U.S., to evaluate safety and efficacy of JAB-30300.
Jacobio Pharma announced it received IND approval of its self-developed drug JAB-30300 from the FDA of the U.S. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the U.S., to evaluate safety and efficacy of JAB-30300.